QuantRankUS equity stock ranking
← Back to ranking
#44Health Care· Biotechnology

INCYBuy

Incyte

$95.31USD
63
Composite Score62.8Strong
−57
Margin of safety−57%Expensive
Fair value$60.68
Target$170.06
Loss chance57%

Price (1y)

Loading price history…

Fair price check

5 different valuation methods each estimate what INCY should be worth, then we compare to today's price.

Looks overvalued
Models suggest INCY is trading above fair value
Today's price
$95.31
Median fair price
$60.68
-36% vs today
Of 5 methods:1 say cheap4 say pricey
  • P/E multiplesUndervalued
    thinks it's a bargain — estimates $170.06, about 78% above today
  • P/B multiplesOvervalued
    thinks it's expensive — estimates $79.54, about 17% below today
  • EV/EBITDAOvervalued
    thinks it's expensive — estimates $60.68, about 36% below today
  • Graham (defensive)Overvalued
    thinks it's expensive — estimates $42.62, about 55% below today
  • Residual IncomeOvervalued
    thinks it's expensive — estimates $29.36, about 69% below today

How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.

Fair price ensemble

Median fair
$60.68
Margin of safety
-57.1%
Max (ex-outliers)
$170.06
Tangible BVPS
$26.29
MethodValue
Graham (defensive)$42.62
P/E multiples(vs sector peers)$170.06
P/B multiples(vs sector peers)$79.54
EV/EBITDA(vs sector peers)$60.68
Residual Income$29.36
DCF (2-stage)skipped
  • restatement history

Median of all applicable methods (current price $95.31). Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.

Pillar breakdown

8 dimensions, each scored 0–100 against the universe

Health Care median (n=59)
  • Quality
    Profit margins & asset efficiency
    67
    Decent
  • Value
    Price vs fundamentals
    45
    Weak
  • Growth
    Revenue & earnings trajectory
    81
    Strong
  • Momentum
    Recent price strength
    50
    Weak
  • Health
    Balance sheet & solvency
    79
    Strong
  • Profitability
    ROE, ROA, ROIC
    89
    Strong
  • Technical
    Trend & volatility signals
    46
    Weak
  • Risk
    Volatility & drawdown profile
    58
    Decent
0305070100
Strong (70+)Decent (50–70)Weak (30–50)Poor (<30)

Pillars not shown: Sentiment, ML (Phase 5+).

Raw fundamentals (SEC EDGAR)

MetricValue
Market cap$19.04B
Revenue (TTM)$5.36B
Net income (TTM)$1.43B
Operating cash flow (TTM)$1.52B
CapEx (TTM)$77.83M
Free cash flow (TTM)CFO − CapEx$1.44B
Total assets$7.34B
Total liabilities$1.72B
Stockholders' equity$5.62B
Cash & equivalents$3.46B
Shares outstanding199.78M
EPS (basic)$1.52
EPS (diluted)$1.47
P/E ratio (TTM)13.30

TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).

Data quality

Latest filed date
2026-04-28
Latest period end
2026-04-21
Filing lag
18 days
Missing metrics
3(gross_profit, dividends_paid, accounts_receivable)

Phase 3c — composite is the 8-pillar weighted score over quality, value, growth, momentum, health, profitability, technical, and risk. Sentiment + ML pillars land in Phases 5-6; until then their weight redistributes pro-rata. Fair price is the median of 6 valuation methods (Graham, P/E / P/B / EV-EBITDA multiples, RIM, DCF) with outliers above 5× current price excluded from the max. Risk-overlay flags annotate only — they suppress the entered-top-5 badge but do not modify the composite.